Skip to main content
Top
Published in: Endocrine Pathology 1/2013

01-03-2013

Follicular Thyroid Carcinoma Presenting as a Massive Chest Wall Tumor

Authors: Ryan Gertz, Rakesh Sarda, Ricardo Lloyd

Published in: Endocrine Pathology | Issue 1/2013

Login to get access

Abstract

The initial presentation of follicular thyroid carcinoma is rarely related to metastatic lesions. Presented here is the case of a 70-year-old woman with the initial presentation of a 13-cm chest wall mass identified as a metastatic follicular thyroid carcinoma. The chest wall lesion had features of a poorly differentiated carcinoma with areas of necrosis, an insular growth pattern focally and increased mitotic activity. A small follicular carcinoma was subsequently identified. The primary tumor was a 1-cm well-differentiated follicular carcinoma with capsular and vascular invasion. This represents a rare presentation of a follicular thyroid carcinoma with initial recognition of a large, dedifferentiated metastatic lesion from a small primary carcinoma. Dedifferentiation and metastasis in the context of microcarcinoma is an exceptionally rare event and suggests other mechanisms may be involved in disease spread other than simply increased cell proliferation.
Literature
1.
go back to reference Segal K, Avigail A, Lubin E, Shpitzer T. Follicular carcinoma of the thyroid. Head Neck 16:533–538, 1994.PubMedCrossRef Segal K, Avigail A, Lubin E, Shpitzer T. Follicular carcinoma of the thyroid. Head Neck 16:533–538, 1994.PubMedCrossRef
2.
go back to reference Shaha AR, Loree TR, Shah JP. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 118:1131–1138, 1995.PubMedCrossRef Shaha AR, Loree TR, Shah JP. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 118:1131–1138, 1995.PubMedCrossRef
3.
go back to reference Shaha AR, Shah JP, Loree TR. Differentiated thyroid cancer presenting initially with distant metastasis. Am J Surg 174:474–476, 1997.PubMedCrossRef Shaha AR, Shah JP, Loree TR. Differentiated thyroid cancer presenting initially with distant metastasis. Am J Surg 174:474–476, 1997.PubMedCrossRef
4.
go back to reference Sugino K, Nagahama M, Kitagawa W, Shibuya H, Ohkuwa K, Yano Y, Uruno T, Akaishi J, Kameyama K, Ito K. Prognosis and prognostic factors for distant metastases and tumor mortality in follicular thyroid carcinoma. Thyroid 21(7):751–757, 2011.PubMedCrossRef Sugino K, Nagahama M, Kitagawa W, Shibuya H, Ohkuwa K, Yano Y, Uruno T, Akaishi J, Kameyama K, Ito K. Prognosis and prognostic factors for distant metastases and tumor mortality in follicular thyroid carcinoma. Thyroid 21(7):751–757, 2011.PubMedCrossRef
5.
go back to reference Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP, Gorman CA. Distant metastasis in differentiated thyroid carcinoma. J Clin Endocrinol Metab 67:501–508, 1988.PubMedCrossRef Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP, Gorman CA. Distant metastasis in differentiated thyroid carcinoma. J Clin Endocrinol Metab 67:501–508, 1988.PubMedCrossRef
6.
go back to reference Nar Demirer A, Ayturk S, Tutuncu N B, Gursoy A, Pak Y, Demirag NG. Unresectable huge sternal and mediastinal metastasis of follicular thyroid carcinoma; radiotherapy as first-line and palliative therapy. Exp Clin Endocrinol Diabetes 117:155–158, 2009.PubMedCrossRef Nar Demirer A, Ayturk S, Tutuncu N B, Gursoy A, Pak Y, Demirag NG. Unresectable huge sternal and mediastinal metastasis of follicular thyroid carcinoma; radiotherapy as first-line and palliative therapy. Exp Clin Endocrinol Diabetes 117:155–158, 2009.PubMedCrossRef
7.
go back to reference Boehm T, Rothouse L, Wartofsky L. Metastatic Occult Follicular Thyroid Carcinoma. JAMA 235:2420–2421, 1976.PubMedCrossRef Boehm T, Rothouse L, Wartofsky L. Metastatic Occult Follicular Thyroid Carcinoma. JAMA 235:2420–2421, 1976.PubMedCrossRef
8.
go back to reference Lissak B, Vannetzel J, Gallouedec N, Berrod J, Rieu M. Solitary skin metastasis as the presenting feature of differentiated thyroid microcarcinoma: report of two cases. J Endocrinol Invest 18:813–816, 1995.PubMed Lissak B, Vannetzel J, Gallouedec N, Berrod J, Rieu M. Solitary skin metastasis as the presenting feature of differentiated thyroid microcarcinoma: report of two cases. J Endocrinol Invest 18:813–816, 1995.PubMed
9.
go back to reference Proye CA, Dromer D, Carnaille B, Gontier A, Goropoulos A, Carpentier P, Lefebvre J, Decoulx M, Wemeau J, Fossati, Sulman C. Is it still worthwhile to treat bone metastases from differentiated thyroid carcinoma with radioactive iodine? World J Surg 16(4):640–646, 1992.PubMedCrossRef Proye CA, Dromer D, Carnaille B, Gontier A, Goropoulos A, Carpentier P, Lefebvre J, Decoulx M, Wemeau J, Fossati, Sulman C. Is it still worthwhile to treat bone metastases from differentiated thyroid carcinoma with radioactive iodine? World J Surg 16(4):640–646, 1992.PubMedCrossRef
10.
go back to reference Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, Lloyd RV, LiVolsi VA, Papotti M, Sobrinho-Simoes M, Bussolati G, Rosai J. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 31(8):1256–1264, 2007.PubMedCrossRef Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, Lloyd RV, LiVolsi VA, Papotti M, Sobrinho-Simoes M, Bussolati G, Rosai J. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 31(8):1256–1264, 2007.PubMedCrossRef
11.
go back to reference Asioli S, Erickson LA, Righi A, Jin L, Volante M, Jenkins S, Papotti M, Bussolati G, Lloyd RV. Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP expression. Mod Pathol 23:1269–1278, 2010.PubMedCrossRef Asioli S, Erickson LA, Righi A, Jin L, Volante M, Jenkins S, Papotti M, Bussolati G, Lloyd RV. Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP expression. Mod Pathol 23:1269–1278, 2010.PubMedCrossRef
12.
go back to reference Machens A, Hinze R, Lautenschlager C, Dralle H. Multivariate analysis of clinicopathologic parameters for the insular subtype of differentiated thyroid carcinoma. Arch Surg 136:941–944, 2001PubMedCrossRef Machens A, Hinze R, Lautenschlager C, Dralle H. Multivariate analysis of clinicopathologic parameters for the insular subtype of differentiated thyroid carcinoma. Arch Surg 136:941–944, 2001PubMedCrossRef
13.
go back to reference Decaussin M, Bernard MH, Adeleine P, Treilleux I, Peix JL, Pugeat M, Tourniaire J, Berger N. Thyroid carcinomas with distant metastases: a review of 111 cases with emphasis on the prognostic significance of an insular component. Am J Surg Pathol 26(8):1007–1015, 2002.PubMedCrossRef Decaussin M, Bernard MH, Adeleine P, Treilleux I, Peix JL, Pugeat M, Tourniaire J, Berger N. Thyroid carcinomas with distant metastases: a review of 111 cases with emphasis on the prognostic significance of an insular component. Am J Surg Pathol 26(8):1007–1015, 2002.PubMedCrossRef
14.
go back to reference Yamashita H, Noguchi Y, Noguchi S, Yamashita H, Uchino S, Watanabe S, Ogawa T, Murakami T. Significant of an insular component in follicular thyroid carcinoma with distant metastasis at initial presentation. Endocr Pathol 16(1):41–48, 2005.PubMedCrossRef Yamashita H, Noguchi Y, Noguchi S, Yamashita H, Uchino S, Watanabe S, Ogawa T, Murakami T. Significant of an insular component in follicular thyroid carcinoma with distant metastasis at initial presentation. Endocr Pathol 16(1):41–48, 2005.PubMedCrossRef
15.
go back to reference Rufini V, Salvatori M, Fadda G, Pinnarelli L, Castaldi P, Maussier ML, Galli G. Thyroid carcinomas with a variable insular component: prognostic significance of histopathologic patterns. Cancer 110:1209–1217, 2007.PubMedCrossRef Rufini V, Salvatori M, Fadda G, Pinnarelli L, Castaldi P, Maussier ML, Galli G. Thyroid carcinomas with a variable insular component: prognostic significance of histopathologic patterns. Cancer 110:1209–1217, 2007.PubMedCrossRef
16.
go back to reference Osaka M, Soga J, Tamiya Y, Suzuki T. Dedifferentiation of neoplastic cells in medullary thyroid carcinoma: report of a case. Surg Today Jpn J Surg 29:1189–1194, 1999.CrossRef Osaka M, Soga J, Tamiya Y, Suzuki T. Dedifferentiation of neoplastic cells in medullary thyroid carcinoma: report of a case. Surg Today Jpn J Surg 29:1189–1194, 1999.CrossRef
17.
go back to reference Knauf J, Sartor M, Medvedovic M, Lundsmith E, Ryder M, Salzano M, Nikiforov Y, Giordano T, Ghossein R, Fagin J. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGF signaling. Oncogene 30(28):3153–3162, 2011.PubMedCrossRef Knauf J, Sartor M, Medvedovic M, Lundsmith E, Ryder M, Salzano M, Nikiforov Y, Giordano T, Ghossein R, Fagin J. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGF signaling. Oncogene 30(28):3153–3162, 2011.PubMedCrossRef
18.
go back to reference Kazaure H, Sanziana R, Sosa J. Insular thyroid carcinoma: a population-level analysis of patient characteristics and predictors of survival. Cancer 118:3260–3267, 2012.PubMedCrossRef Kazaure H, Sanziana R, Sosa J. Insular thyroid carcinoma: a population-level analysis of patient characteristics and predictors of survival. Cancer 118:3260–3267, 2012.PubMedCrossRef
19.
go back to reference Saiz A, Olvera M, Rezk S, Florentine B, McCourty A, Brynes R. Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions. J Pathol 198:157–162, 2002.PubMedCrossRef Saiz A, Olvera M, Rezk S, Florentine B, McCourty A, Brynes R. Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions. J Pathol 198:157–162, 2002.PubMedCrossRef
20.
go back to reference Tan A, Etit D, Bayol U, Altinel D, Tan S. Comparison of proliferating cell nuclear antigen, thyroid transciption factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma and follicular adenoma. Ann Diagn Pathol 15(2):108–116, 2011.PubMedCrossRef Tan A, Etit D, Bayol U, Altinel D, Tan S. Comparison of proliferating cell nuclear antigen, thyroid transciption factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma and follicular adenoma. Ann Diagn Pathol 15(2):108–116, 2011.PubMedCrossRef
21.
go back to reference Erickson LA, Jin L, Wollan PC, Thompson GB, Heerden Jv, Lloyd RV. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors. Modern Pathology 11:169–174, 1998.PubMed Erickson LA, Jin L, Wollan PC, Thompson GB, Heerden Jv, Lloyd RV. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors. Modern Pathology 11:169–174, 1998.PubMed
22.
go back to reference Mussig K, Wehrmann T, Dittmann H, Wehrmann M, Uederberg B, Schulz S, Bares R, Petersenn S. Expression of the proliferation marker Ki-67 associates with tumour staging and clinical outcome in differentiated thyroid carcinomas. Clin Endo 77:139–145, 2012.CrossRef Mussig K, Wehrmann T, Dittmann H, Wehrmann M, Uederberg B, Schulz S, Bares R, Petersenn S. Expression of the proliferation marker Ki-67 associates with tumour staging and clinical outcome in differentiated thyroid carcinomas. Clin Endo 77:139–145, 2012.CrossRef
Metadata
Title
Follicular Thyroid Carcinoma Presenting as a Massive Chest Wall Tumor
Authors
Ryan Gertz
Rakesh Sarda
Ricardo Lloyd
Publication date
01-03-2013
Publisher
Springer US
Published in
Endocrine Pathology / Issue 1/2013
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-012-9227-6

Other articles of this Issue 1/2013

Endocrine Pathology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.